⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of ChuanXin Biomedicine and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
ChuanXin Biomedicine
↗Suzhou, China
ChuanXin Biomedicine is a biotechnology company focused on the commercial development of RNA-based therapeutics. The company utilizes advanced lipid nanoparticle (LNP) delivery technologies to develop mRNA vaccines for infectious diseases and oncology, as well as exploring applications in targeted therapy and protein replacement.
Founded in 2021 and headquartered in the Suzhou Industrial Park, the company has established a comprehensive R&D and manufacturing infrastructure for mRNA drugs. It maintains strategic collaborations, including technology partnerships with Acuitas Therapeutics, and is backed by significant venture capital and strategic investment from firms like Baike Bio.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:<$5M
Founded:2021
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$20M+
Investors:Baike Bio, CCB International, Yuansheng Venture Capital, Huagai Capital, Hongtai Fund
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1 / IIT
Modalities:mRNA, LNP delivery
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Acuitas Therapeutics (LNP delivery technology)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Chen Jianxin - Chairman/CEO
LINKS
Website:themediumtx.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with ChuanXin Biomedicine. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.